Company intelligence / Profile preview

NitroMed, Inc.

Lexington, Massachusetts, United Statessec.gov ↗

Ownership: Private
Employees: ~100
Development stage: Phase 3

Overview

NitroMed developed BiDil, an orally administered medicine for the treatment of heart failure in self-identified black patients. BiDil was approved by the FDA primarily based on efficacy data from the company's A-HeFT (African American Heart Failure Trial) clinical trial.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BiDil

Phase 3

Indications: Heart failure in African Americans

Beyond the preview

Go deeper on NitroMed, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NitroMed, Inc..

Explore the full profile